PNC Financial Services Group
AVTX icon

PNC Financial Services Group’s Avalo Therapeutics AVTX Stock Holding History

PNC Financial Services Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Hold
0
– -$10 – 4736
2023
Q1 		– Hold
0
– – – 4656
2022
Q4 		– Hold
0
– – – 4735
2022
Q3 		– Hold
0
– – – 4443
2022
Q2 		– Hold
0
– – – 4479
2022
Q1 		– Hold
0
– – – 4516
2021
Q4 		– Sell
-3
Closed -$18K – 4441
2021
Q3 		$22K Hold
3
– – ﹤0.01% 3453
2021
Q2 		$33K Hold
3
– – ﹤0.01% 3265
2021
Q1 		$30K Hold
3
– – ﹤0.01% 3234
2020
Q4 		$26K Hold
3
– – ﹤0.01% 3218
2020
Q3 		$23K Buy
+3
New +$22.5K ﹤0.01% 3154

Other funds holding AVTX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group's AVTX Position: Q2 2023 in Review

PNC Financial Services Group held its Avalo Therapeutics (AVTX) position steady in Q2 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4736.

PNC Financial Services Group first reported a position in AVTX in Q3 2020 and has held it in 5 quarters since. The position peaked at $33K in Q2 2021. 22 funds tracked by Wall St. Rank hold AVTX as of Q2 2023.

  • PNC Financial Services Group held 0 shares of Avalo Therapeutics worth $0 as of Q2 2023.
  • PNC Financial Services Group left its Avalo Therapeutics share count unchanged in Q2 2023.
  • Avalo Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2023, its #4736 holding.
  • PNC Financial Services Group first reported a position in Avalo Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • PNC Financial Services Group's Avalo Therapeutics position peaked at $33K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2023.

Based on PNC Financial Services Group's 13F filing for Q2 2023, filed 11 Aug 2023.